Vistagen Therapeutics, Inc. Net Income Loss

• Vistagen Therapeutics, Inc. showed a decrease of -75.1% in Net Income Loss from 2024 to 2025.
• This data is from Vistagen Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
• XBRL data for this metric is available from 2001 to 2025 (25 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 25 years of available data (2001 to 2025), Vistagen Therapeutics, Inc.'s Net Income Loss has declined by 2,742.3%.
• Historical annual values: Fiscal year 2025: -$51.42 million | Fiscal year 2024: -$29.36 million | Fiscal year 2023: -$59.25 million | Fiscal year 2022: -$47.76 million | Fiscal year 2021: -$17.93 million | Fiscal year 2020: -$20.77 million | Fiscal year 2019: -$24.59 million | Fiscal year 2018: -$14.35 million | Fiscal year 2017: -$10.26 million | Fiscal year 2016: -$47.22 million | Fiscal year 2015: -$13.89 million | Fiscal year 2014: -$2.97 million | Fiscal year 2013: -$12.89 million | Fiscal year 2012: -$12.21 million | Fiscal year 2011: -$9.48 million | Fiscal year 2010: -$4.12 million | Fiscal year 2009: -$4.70 million | Fiscal year 2008: -$5.45 million | Fiscal year 2007: -$2.00 million | Fiscal year 2006: -$1.77 million | Fiscal year 2005: -$1.08 million | Fiscal year 2004: -$8.76 million | Fiscal year 2003: -$502.6 thousand | Fiscal year 2002: -$2.11 million | Fiscal year 2001: -$1.81 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026